FREE Account Opening + No Clearing Fees
Loading...

Bafna Pharmaceuticals IPO vs MCX IPO

Comparision between Bafna Pharmaceuticals IPO and MCX IPO.

IPO Details

Bafna Pharmaceuticals IPO is a Mainline Book Built Issue IPO proposed to list at BSE while MCX IPO is a Mainline Book Built Issue proposed to list at BSE.

  Bafna Pharmaceuticals IPO MCX IPO
Logo Bafna Pharmaceuticals IPO Logo MCX IPO Logo
Issue Category Mainline Mainline
Issue Type IPO IPO
Process Type Fixed Price Issue Book Built Issue
Listing At BSE BSE
Lead Managers Keynote Financial Services Ltd

Ashika Capital Ltd
Citigroup Global Markets India Private Limited

Edelweiss Financial Services Ltd

Morgan Stanley India Company Pvt Ltd
Registrar Cameo Corporate Services Limited Kfin Technologies Limited
Market Maker
DRHP DRHP DRHP
RHP RHP
Anchor Investor
IPO Allotment URL IPO Allotment URL IPO Allotment URL

Issue Size and Price

The total issue size of Bafna Pharmaceuticals IPO is up to ₹25.60 Cr whereas the issue size of the MCX IPO is up to ₹663.31 Cr. The final issue price of Bafna Pharmaceuticals IPO is ₹40.00 per share and of MCX IPO is ₹1,032.00 per share.

  Bafna Pharmaceuticals IPO MCX IPO
Face Value ₹10 per share ₹10 per share
Issue Price (Lower) ₹860.00 per share
Issue Price (Upper) ₹1,032.00 per share
Issue Price (Final) ₹40.00 per share ₹1,032.00 per share
Discount (Retail)
Discount (Employee)
Market Lot Size 6 shares
Fresh Issue Size
Fresh Issue Size (Amount)
OFS Issue Size
OFS Issue Size (Amount)
Issue Size Total 64,00,000 shares 64,27,378 shares
Issue Size Total (Amount) up to ₹25.60 Cr up to ₹663.31 Cr

IPO Timetable

Bafna Pharmaceuticals IPO opens on May 27, 2008, while MCX IPO opens on Feb 22, 2012. The closing date of Bafna Pharmaceuticals IPO and MCX IPO is May 30, 2008, and Feb 24, 2012, respectively.

  Bafna Pharmaceuticals IPO MCX IPO
Anchor Bid Date
Issue Open May 27, 2008 Feb 22, 2012
Issue Close May 30, 2008 Feb 24, 2012
Basis Of Allotment (Tentative)
Initiation of Refunds (Tentative)
Credit of Share (Tentative)
Listing date (Tentative)
Anchor Lockin End date 1
Anchor Lockin End date 2

Financials

Bafna Pharmaceuticals IPO P/E ratio is , as compared to MCX IPO P/E ratio of .

  Bafna Pharmaceuticals IPO MCX IPO
Financial
ParticularsFor the year/period ended (Rs. in lacs)
 30-Jun-0731-Mar-0731-Mar-0631-Mar-0531-Mar-04
  Total Income432.023861.962136.472662.651521.33
  Profit After Tax (PAT)49.70104.2392.2789.8144.51
ParticularsFor the year/period ended (in Rs. Million)
31-Dec-1131-Mar-1131-Mar-1031-Mar-09
Total Income4,745.024,475.604,937.013,658.44
Profit After Tax (PAT)2,205.341,730.972,207.261,574.19

Read MCX Annual Reports

Promoter Shareholding (Pre-Issue)
Promoter Shareholding (Post-Issue)
P/E Ratio
Market Cap
ROE
ROCE
Debt/Equity
EPS
RoNW

Shares Offered

In the Bafna Pharmaceuticals IPO retail investors (RII) are offered while in MCX IPO retail investors are offered . Qualified institutional buyers (QIB) are offered in Bafna Pharmaceuticals IPO and 21,62,083 shares in MCX IPO.

  Bafna Pharmaceuticals IPO MCX IPO
Anchor Investor Reserveration
Market Maker Reserveration
QIB 21,62,083 shares
NII 9,26,607 shares
RII 21,62,082 shares
Employee 2,50,000 shares
Others
Total 55,00,772 shares

Bids Received (Subscription)

Bafna Pharmaceuticals IPO subscribed in total, whereas MCX IPO subscribed 54.13x.

  Bafna Pharmaceuticals IPO MCX IPO
QIB (times) 49.12x
NII (times) 150.35x
Big NII (times)
Small NII (times)
RII (times) 24.14x
Employee (times) 0.18x
Other (times)
Total (times) 54.13x

Comments

Add a public comment...